We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Novartis has acquired US-based software startup Amblyotech, which is developing a digital treatment for amblyopia (lazy eye) that leads to vision loss in children and young adults.